Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type

NCT02248116 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Talsaclidine

Sponsor

Boehringer Ingelheim